Recombinant DNA Technology for the Production of Plasma Proteins
During the past few years we have seen an unparalleled interest and growth in applied biology. The rapid progress in this area has been largely driven by laboratory advances in monoclonal antibody and recombinant DNA (r-DNA) techniques. Most of the early efforts to apply r-DNA technology to commercial product development were directed toward the production of small peptide hormones such as interferon, insulin and growth hormone. The only r-DNA produced therapeutic agent currently on the market is the human insulin preparation sold by Eli Lilly and Company. However, many observers believe that a human growth hormone preparation produced by Genentech could be available in 1985 and a number of other therapeutic agents such as tissue plasminogen activator are presently undergoing clinical trials.
KeywordsFactor VIII Human Albumin Plasma Fractionation Large Scale Fermentation Fermentation Capacity
Unable to display preview. Download preview PDF.
- 1.Andersson L-O, Serum albumin, In: Blomback B; Hanson Lft, eds. Plasma Proteins. New York. John Wiley & Sons, 1979:43–71.Google Scholar
- 2.Food and Drug Administration. FDA talk paper T83-2: Regulating recombinant DNA products, January 7, 1983, Rockville, MD,: U.S. Department of Health and Human Services Public Health Service.Google Scholar
- 6.Fulcher CA, Zimmerman TS. Characterization of the human factor VIII procoagulant protein with a heterologous precipitating antibody. Proc Natl Acad Sci USA 1982;1648–52.Google Scholar
- 7.Shapiro SS, Hultin M. Acquired inhibitors to the blood coagulation factors. Semin Thrombos Hemostas 1975;1:336–44.Google Scholar
- 8.Andersson L-0. Haemophilia B-factor (factor IX), In: Blomback B, Hanson Lft, eds. Plasma Proteins, New York. John Wiley & Sons, 1979:281–5.Google Scholar
- 9.Chase M. Genentech claims ’First1 in technology to make antibodies: Firm, City of Hope medical scientists use techniques of Genetic engineering. Wall Street Journal 1983;May 5.Google Scholar